Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25179190 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Kenichiro Ishikawa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan. Hauptthemen laut MEDLINE: Hyaluronan Receptors, Mouth Neoplasms, Antibodies, Monoclonal, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
CD44 regulates cell adhesion, proliferation, survival, and stemness and has been considered a tumor therapy target. CD44 possesses the shortest CD44 standard (CD44s) and a variety of CD44 variant (CD44v) isoforms. Since the expression of CD44v is restricted in epithelial cells and carcinomas compared to CD44s, CD44v has been considered a promising target for monoclonal antibody (mAb) therapy. We previously developed an anti-CD44v10 mAb, C44Mab-18 (IgM, kappa), to recognize the variant exon 10-encoded region. In the present study, a mouse IgG2a version of C44Mab-18 (C44Mab-18-mG2a) was generated to evaluate the antitumor activities against CD44-positive cells compared with the previously established anti-pan CD44 mAb, C44Mab-46-mG2a. C44Mab-18-mG2a exhibited higher reactivity compared with C44Mab-46-mG2a to CD44v3–10-overexpressed CHO-K1 (CHO/CD44v3–10) and oral squamous cell carcinoma cell lines (HSC-2 and SAS) in flow cytometry. C44Mab-18-mG2a exerted a superior antibody-dependent cellular cytotoxicity (ADCC) against CHO/CD44v3–10. In contrast, C44Mab-46-mG2a showed a superior complement-dependent cytotoxicity (CDC) against CHO/CD44v3–10. A similar tendency was observed in ADCC and CDC against HSC-2 and SAS. Furthermore, administering C44Mab-18-mG2a or C44Mab-46-mG2a significantly suppressed CHO/CD44v3–10, HSC-2, and SAS xenograft tumor growth compared with the control mouse IgG2a. These results indicate that C44Mab-18-mG2a could be a promising therapeutic regimen for CD44v10-positive tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan.
- Department of Otolaryngology, Head and Neck Surgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan.
- Institute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation, 18-24 Miyamoto, Numazu-shi 410-0301, Shizuoka, Japan.
- Institute of Microbial Chemistry (BIKAKEN), Laboratory of Oncology, Microbial Chemistry Research Foundation, 3-14-23 Kamiosaki, Shinagawa-ku, Tokyo 141-0021, Japan.
ORCID-Profile: Hiroyuki Suzuki, Tomokazu Ohishi, Guanjie Li, Manabu Kawada, Akira Ohkoshi, Mika K Kaneko, Yukinari Kato
Förderung
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
Zitieren
APA
Ishikawa, K., Suzuki, H., Ohishi, T., Li, G., Tanaka, T., Kawada, M., Ohkoshi, A., Kaneko, M. K., Katori, Y., & Kato, Y. (2024). Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25179190
Vancouver
Ishikawa K, Suzuki H, Ohishi T, Li G, Tanaka T, Kawada M, et al. Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25179190
BibTeX
@article{Ishikawa2024,
author = {Ishikawa, Kenichiro and Suzuki, Hiroyuki and Ohishi, Tomokazu and Li, Guanjie and Tanaka, Tomohiro and Kawada, Manabu and Ohkoshi, Akira and Kaneko, Mika K and Katori, Yukio and Kato, Yukinari},
title = {Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25179190}
}
EUVIMED